ÂÜÀòÂÒÂ×

Most recently, Dr. Lv served as Head of Translational Medicine for CSPC Group where he built Clinical Pharmacology, Biomarker & CDx, Bioanalytics, and Publication Strategy functions to support the company’s clinical pipeline. In this role, he led multiple regulatory interactions in China and Australia. Prior to joining CSPC, Dr. Lv was Senior Director, Scientific Engagement & Development at Covance. Prior to Covance, he was with Roche and GSK for 10 years, leading multiple Phase I – Phase III clinical programs in the US, Europe, Asia Pacific, and China across therapeutic areas including oncology, immunology, infectious disease, cardiovascular, metabolic, neuroscience, urology, rare diseases, and dermatology. Dr. Lv’s work has been published in key journals including The Lancet Oncology, Antimicrobial Agents and Chemotherapy, European Journal of Pharmaceutics and Biopharmaceutics, and presented at top congresses including the ASM/ICAAC annual meeting, Asian Pharmacometrics Conference. He is an Editorial Board Member of the textbook Research on Pharmacokinetics - Pharmacodynamics. Dr. Lv is a member of the China Oncology Phase I Consortium, the Chinese Anti-Cancer Association, the Chinese Pharmacology Society, and the Shanghai Pharmaceutical Society. He received his Doctor of Engineering degree in Clinical Pharmacology and Pharmacometrics from Huashan Hospital, Fudan University.